title: Implications of emerging risk factors for therapeutic intervention.
abstract: Recently, the National Cholesterol Education Panel (NCEP) of the United States of America commented on the implications of new clinical trials for the Adult Treatment Panel III (ATP III) guidelines. In this commentary, new categories of "moderately high" and "very high" coronary risk were proposed with new "therapeutic options" for low-density lipoprotein (LDL) cholesterol of < or = 100 mg/dL and < or = 70 mg/dL respectively. In ATP III, these "moderately high" risk patients had been classified as moderate risk with an LDL treatment goal of < or = 130 mg/dL, while the "very high" risk patients had been classified as high risk with a treatment goal of < or = 100 mg/dL. Risk classification in the new NCEP publication is based essentially on the combination of the Framingham risk score plus counting of classical risk factors. In the present document, the International Task Force for Prevention of Coronary Heart Disease responds to this NCEP commentary and supports the suggestion of more intensive LDL cholesterol lowering in particular cases. However, the Task Force feels that a classification based on a combination of a risk score plus a count of emerging risk factors is a more logical way to identify such patients requiring lower LDL cholesterol levels than a scheme in which classical risk factors are taken into account twice, once in a count and once in a risk score.
authors.affiliation: Institut für Klinische Chemie und Laboratoriumsmedizin, Universitätsklinikum Münster, Münster, Germany. assmann@uni-muenster.de
authors.forename: Gerd
authors.initials: G
authors.lastname: Assmann
authors.forename: Paul
authors.initials: P
authors.lastname: Cullen
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Fruchart
authors.forename: Heiner
authors.initials: H
authors.lastname: Greten
authors.forename: Marek
authors.initials: M
authors.lastname: Naruszewicz
authors.forename: Anders
authors.initials: A
authors.lastname: Olsson
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Paoletti
authors.forename: Walter
authors.initials: W
authors.lastname: Riesen
authors.forename: Monika
authors.initials: M
authors.lastname: Stoll
authors.forename: Matti
authors.initials: M
authors.lastname: Tikkanen
authors.forename: Arnold
authors.initials: A
authors.lastname: von Eckardstein
mesh_terms: D026683:Advisory Committees; D000465:Algorithms; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000145:classification* / Q000517:prevention & control / Q000628:therapy*; D008078:Cholesterol, LDL / Q000097:blood*; D005060:Europe; D017048:Health Care Costs; D006710:Homocysteine / Q000097:blood; D006801:Humans; D007391:International Cooperation; D017270:Lipoprotein(a) / Q000097:blood; D017410:Practice Guidelines as Topic; D012016:Reference Values; D018570:Risk Assessment; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014481:United States
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D017270:Lipoprotein(a); D006710:Homocysteine; D002097:C-Reactive Protein